The Effect of Rifaximin on Portal Vein Thrombosis

• Status: Unknown status
• Trial end date: 2019-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the efficacy of rifaximin in the treatment of portal vein thrombosis in cirrhotic patients

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Zhongshan Hospital
• Treatments: Rifamycins; Rifaximin

Criteria

Inclusion Criteria:

• 18 y.o. ≤age≤75 y.o

• Cirrhotic patients had CTA confirmed portal vein trombosis

• D-dimer no more than five times the normal upper limit

Exclusion Criteria:

• age <18 y.o. or age > 75 y.o.

• had portal cavernoma

• received anticoagulation treatment in the past 6 months

• splenectomy

• Known infection after endoscopic treatment (Fever, microbial cultures positive, et al.)

• Massive ascites or combined with other high risk factor that require prophylaxis use of antibiotics.

• Acute variceal bleeding within 5 days.

• Use of other antibiotics in the past 2 weeks

• Acute portal vein thrombosis